V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20215393 | 20081516 | 1.62 | 115 | Palliative (P) | 2017-06-30 | 2017-07-05 | Trial Unspecified | Y | N | TRIAL | 100929798 |
| 20215394 | 20081517 | 1.72 | 81.3 | Curative (C) | 2017-05-04 | 2017-05-04 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101294458 |
| 20215395 | 20081518 | 1.56 | 78 | Palliative (P) | 2016-08-13 | 2016-08-27 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100568449 |
| 20215397 | 20081519 | 1.78 | 63.6 | Palliative (P) | 2018-06-10 | 2018-06-25 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100150669 |
| 20215398 | 20081520 | 1.63 | 60 | 03 | 2016-10-16 | 2016-10-18 | LANREOTIDE | 02 | N | LANREOTIDE | 101144790 |
| 20215399 | 20081521 | 1.66 | 83.2 | Curative (C) | 2018-07-29 | 2018-08-29 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101588104 |
| 20215400 | 20081522 | null | null | null | 2017-05-11 | 2017-05-20 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | LANREOTIDE | 101715243 |
| 20215401 | 20081523 | null | null | 03 | 2020-02-07 | 2020-02-07 | LANREOTIDE | 02 | N | LANREOTIDE | 101848867 |
| 20215402 | 20081524 | 1.66 | 50.4 | Palliative (P) | 2016-08-08 | 2016-08-22 | Cetuximab + FOLFIRI cycle 2 onwards | null | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100586356 |
| 20215403 | 20081525 | 1.73 | 54.2 | Curative (C) | 2017-03-25 | 2017-04-08 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100550894 |
| 20215404 | 20081526 | null | null | Palliative (P) | 2019-09-10 | 2019-09-16 | LANREOTIDE | 02 | N | LANREOTIDE | 101527618 |
| 20215405 | 20081527 | 1.9 | 70.2 | Curative (C) | 2020-02-21 | 2020-03-08 | HCX | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100407020 |
| 20215407 | 20081528 | 1.49 | 72.3 | Palliative (P) | 2019-05-21 | 2019-05-29 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100679586 |
| 20215408 | 20081529 | 1.58 | 0 | Palliative (P) | 2017-10-01 | 2017-10-10 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100976664 |
| 20215409 | 20081530 | 1.66 | 75 | null | 2019-11-12 | 2019-11-12 | CETUXIMAB + IRINOTECAN + MDG | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100370168 |
| 20215412 | 20081532 | 0 | 62 | Adjuvant (A) | 2018-02-20 | 2018-02-27 | IMATINIB | 02 | N | IMATINIB | 101315687 |
| 20215413 | 20081533 | 1.68 | 73 | Radical (R) | 2016-12-19 | 2017-01-18 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100988285 |
| 20215415 | 20081534 | 1.69 | 79 | Curative (C) | 2018-09-28 | 2018-10-17 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100805659 |
| 20215417 | 20081536 | 1.74 | 57.7 | Curative (C) | 2018-12-22 | 2019-01-16 | Fluorouracil+Mitomycin+RT (Anal Ca) | 2 | Y | FLUOROURACIL + MITOMYCIN + RT | 101228387 |
| 20215419 | 20081538 | null | 80.7 | Curative (C) | 2019-07-25 | 2019-07-25 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101006178 |
| 20215420 | 20081539 | 1.76 | 83 | Palliative (P) | 2016-05-15 | 2016-06-03 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101365679 |
| 20215421 | 20081540 | 1.67 | 120 | Curative (C) | null | 2017-03-12 | HCX (Cape + Cisp + Tras) - Load | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100835833 |
| 20215422 | 20081541 | 1.69 | 58 | Adjuvant (A) | null | 2014-01-17 | null | N | N | TRIAL | 100248825 |
| 20215424 | 20081543 | 1.65 | null | Curative (C) | 2018-06-21 | 2018-07-13 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100294122 |
| 20215426 | 20081544 | 1.67 | 66.75 | null | 2016-12-20 | 2017-01-17 | LANREOTIDE | 02 | N | LANREOTIDE | 100307398 |
| 20215427 | 20081545 | 1.65 | 71.5 | Palliative (P) | 2017-08-21 | 2017-08-26 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101090697 |
| 20215428 | 20081546 | 1.65 | null | Palliative (P) | 2017-07-12 | 2017-08-02 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101328549 |
| 20215429 | 20081547 | 1.85 | 68.85 | Curative (C) | 2016-02-06 | 2016-03-04 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100115985 |
| 20215430 | 20081548 | 1.91 | 89 | Curative (C) | 2016-07-04 | 2016-07-14 | Fluorouracil+Mitomycin+RT (Anal Ca) | 2 | Y | FLUOROURACIL + MITOMYCIN + RT | 101228771 |
| 20215432 | 20081550 | null | null | Palliative (P) | 2019-05-17 | 2019-06-14 | GO2 TRIAL | Y | N | TRIAL | 100176959 |
| 20215433 | 20081551 | 1.6 | 65 | Curative (C) | 2019-05-14 | 2019-06-14 | FLUOROURACIL + MITOMYCIN + RT | N | null | FLUOROURACIL + MITOMYCIN + RT | 100254615 |
| 20215434 | 20081552 | null | 0 | Palliative (P) | 2020-06-18 | 2020-06-30 | LANREOTIDE | 02 | N | LANREOTIDE | 100796630 |
| 20215435 | 20081553 | 1.62 | null | Palliative (P) | 2018-03-16 | 2018-03-28 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101444909 |
| 20215438 | 20081555 | 0 | 78.5 | null | 2018-05-26 | 2018-05-26 | LANREOTIDE | 02 | N | LANREOTIDE | 101292259 |
| 20215439 | 20081556 | null | 73 | null | 2018-07-14 | 2018-07-22 | LANREOTIDE | 02 | null | LANREOTIDE | 100949939 |
| 20215441 | 20081557 | 1.73 | 0 | 03 | 2017-07-11 | 2017-07-13 | IMATINIB | 02 | N | IMATINIB | 101564484 |
| 20215442 | 20081558 | 1.75 | 72.8 | Palliative (P) | 2020-09-24 | 2020-10-11 | HCX (Cape + Cisp + Tras) - Load | 02 | N | IMATINIB | 101053406 |
| 20215444 | 20081560 | 1.62 | 58.3 | null | 2017-12-06 | 2017-12-07 | Cape+Cisplatin+Trastuzumab Load | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101141866 |
| 20215446 | 20081562 | 1.6 | 76.3 | Palliative (P) | 2018-09-22 | 2018-10-12 | GO2 TRIAL | N | N | TRIAL | 100049597 |
| 20215449 | 20081564 | 1.55 | 78.8 | Curative (C) | 2019-10-02 | 2019-10-17 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101045602 |
| 20215451 | 20081565 | 1.84 | 72.6 | Palliative (P) | 2019-03-16 | 2019-04-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100498051 |
| 20215452 | 20081566 | 1.7 | 70.6 | null | 2018-09-17 | 2018-09-21 | Trial Unspecified | Y | null | TRIAL | 100328414 |
| 20215453 | 20081567 | 1.75 | 86.5 | Curative (C) | 2016-10-17 | 2016-11-09 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101667425 |
| 20215454 | 20081568 | 1.79 | 82.8 | Neo-adjuvant (N) | 2016-03-13 | 2016-03-13 | Trial Unspecified | N | null | TRIAL | 100007338 |
| 20215456 | 20081569 | 1.54 | 51.6 | Palliative (P) | 2017-09-07 | 2017-09-24 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101563720 |
| 20215458 | 20081570 | 1.62 | 0 | Palliative (P) | 2018-10-24 | 2018-11-10 | Imatinib 400mg | 02 | N | IMATINIB | 100118134 |
| 20215459 | 20081571 | 1.54 | 74 | Palliative (P) | 2019-06-06 | 2019-06-07 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100808737 |
| 20215461 | 20081572 | 1.8 | 0 | Curative (C) | 2018-04-20 | 2018-04-22 | GO2 TRIAL | Y | Y | TRIAL | 100778569 |
| 20215462 | 20081573 | null | 96.2 | Palliative (P) | 2021-06-06 | 2021-06-06 | LANREOTIDE | 02 | N | LANREOTIDE | 101519566 |
| 20215463 | 20081574 | 1.61 | 47.6 | Palliative (P) | 2019-08-24 | 2019-09-11 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100431276 |